Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
Johan Burisch, Mirabella Zhao, Selwyn Odes, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 5, pp. 458-492
Open Access | Times Cited: 81

Showing 26-50 of 81 citing articles:

Characterization of patient-derived intestinal organoids for modelling fibrosis in Inflammatory Bowel Disease
Ilaria Laudadio, Claudia Carissimi, Noemi Scafa, et al.
Inflammation Research (2024) Vol. 73, Iss. 8, pp. 1359-1370
Open Access | Times Cited: 4
Alleviating Pyroptosis of Intestinal Epithelial Cells to Restore Mucosal Integrity in Ulcerative Colitis by Targeting Delivery of 4-Octyl-Itaconate
Wenying Li, Dong Chen, Yanmei Zhu, et al.
ACS Nano (2024) Vol. 18, Iss. 26, pp. 16658-16673
Closed Access | Times Cited: 4
IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management
Pablo Vega, J M Huguet, Ernesto A. Gómez, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 3, pp. 749-765
Open Access | Times Cited: 3
Aryl Hydrocarbon Receptor Regulates Muc2 Production Independently of IL-22 during Colitis
Archana Saxena, Chandani Mitchell, Raymond Bogdon, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2404-2404
Open Access | Times Cited: 3
Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990-2019
Saqr Alsakarneh, Mohamed Ahmed, Fouad Jaber, et al.
Annals of Gastroenterology (2024)
Open Access | Times Cited: 3
Plasma‐Activated Solutions Mitigates DSS‐Induced Colitis via Restoring Redox Homeostasis and Reversing Microbiota Dysbiosis
Tuanhe Sun, Kaijie Ren, Guimin Xu, et al.
Advanced Science (2023) Vol. 10, Iss. 34
Open Access | Times Cited: 9
Nutritional Risk and Sarcopenia Features in Patients with Crohn’s Disease: Relation to Body Composition, Physical Performance, Nutritional Questionnaires and Biomarkers
Konstantinos Papadimitriou, Paraskevi Detopoulou, Konstantinos Soufleris, et al.
Nutrients (2023) Vol. 15, Iss. 16, pp. 3615-3615
Open Access | Times Cited: 8
Higher Dietary Quercetin Intake Is Associated with Lower Risk of Adverse Outcomes among Individuals with Inflammatory Bowel Disease in a Prospective Cohort Study
Tianyu Wang, Shiyuan Lu, Lintao Dan, et al.
Journal of Nutrition (2024) Vol. 154, Iss. 6, pp. 1861-1868
Closed Access | Times Cited: 2
High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked Clinical and Health Administrative Data
M Ellen Kuenzig, Thomas D. Walters, David Mack, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 2
Dietary Lactobacillus johnsonii-derived extracellular vesicles ameliorate acute colitis by regulating gut microbiota and maintaining intestinal barrier homeostasis
Zhiguo Li, Mengyu Li, Xuexun Fang, et al.
Food & Function (2024)
Closed Access | Times Cited: 2
Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service
Shellie Radford, Buraq Abdul-Aema, Chris R. Tench, et al.
Scandinavian Journal of Gastroenterology (2024) Vol. 59, Iss. 6, pp. 683-689
Open Access | Times Cited: 2
Investigating the Crime Scene—Molecular Signatures in Inflammatory Bowel Disease
Vibeke Andersen, Tue Bjerg Bennike, Corinna Bang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11217-11217
Open Access | Times Cited: 6
De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review
Javier P. Gisbert, María Chaparro
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 4, pp. 642-658
Closed Access | Times Cited: 6
Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis
E Brunet, B Garcia-Sagué, Emili Vela, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
PIM1–HDAC2 axis modulates intestinal homeostasis through epigenetic modification
Jianming Yang, Yawen Xiao, Ningning Zhao, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 7, pp. 3049-3067
Open Access | Times Cited: 1
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Celia Gómez-Labrador, E Ricart, Marisa Iborra, et al.
Pharmaceutics (2024) Vol. 16, Iss. 5, pp. 629-629
Open Access | Times Cited: 1
Exploring the foundations of a digital health information service for patients with inflammatory bowel disease: a mixed method study in Gravitate-Health
Sigurd Maurud, Lene Lunde, Anne Moen, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Mortality of Patients With Inflammatory Bowel Disease in the Faroe Islands From 1966-2020
Kári Rubek Nielsen, Søren Lophaven, Jóngerð Midjord, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 1
Inhibition of Transmural Inflammation in Crohn’s Disease by Orally Administered Tumor Necrosis Factor-Alpha Deoxyribozymes-Loaded Pyroptosis Nanoinhibitors
Zhun Li, Zhenxing Zhu, Dongtao Zhou, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 31, pp. 40499-40514
Closed Access | Times Cited: 1
Real-World Treatment Outcomes Associated with Early Versus Delayed Vedolizumab Initiation in Patients with Ulcerative Colitis
Noa Krugliak Cleveland, Ninfa Candela, John A. Carter, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 4
Open Access | Times Cited: 1
Managing inflammatory bowel disease: what to do when the best is unaffordable?
Rupa Banerjee, Nalini Raghunathan, Partha Pal
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 5, pp. 396-398
Closed Access | Times Cited: 4
The Epidemiology of Inflammatory Bowel Disease in Oceania: A Systematic Review and Meta-Analysis of Incidence and Prevalence
Angela Forbes, Chris Frampton, Andrew S. Day, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 11, pp. 2076-2086
Open Access | Times Cited: 4
Economics of Emergency Department Visits by Patients With Inflammatory Bowel Disease: A Real-World Analysis
Kofi Clarke, Arsh Momin, Michelle Rosario, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 1
Insurer Medication Utilization Barriers are Associated with Decreased Insurance Satisfaction and Adverse Clinical Outcomes: An IBD Partners Survey
Brad D. Constant, Millie D. Long, Frank I. Scott, et al.
The American Journal of Gastroenterology (2024) Vol. 119, Iss. 10, pp. 2070-2078
Closed Access | Times Cited: 1
Molecular targets associated with ulcerative colitis and the benefits of atractylenolides-based therapy
Huanzhu Qian, Zhen Ye, Yu Hu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1

Scroll to top